These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 38211640)

  • 1. Intradermal delivery of the antiretroviral drugs cabotegravir and rilpivirine by dissolving microarray patches: Investigation of lymphatic uptake.
    Ramöller IK; Volpe-Zanutto F; Vora LK; Abbate MTA; Hutton ARJ; McKenna PE; Peng K; Tekko IA; Sabri A; McAlister E; McCarthy HO; Paredes AJ; Donnelly RF
    J Control Release; 2024 Feb; 366():548-566. PubMed ID: 38211640
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Development and Evaluation of Dissolving Microarray Patches for Co-administered and Repeated Intradermal Delivery of Long-acting Rilpivirine and Cabotegravir Nanosuspensions for Paediatric HIV Antiretroviral Therapy.
    Moffatt K; Tekko IA; Vora L; Volpe-Zanutto F; Hutton ARJ; Mistilis J; Jarrahian C; Akhavein N; Weber AD; McCarthy HO; Donnelly RF
    Pharm Res; 2023 Jul; 40(7):1673-1696. PubMed ID: 36224503
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Design, formulation and evaluation of novel dissolving microarray patches containing a long-acting rilpivirine nanosuspension.
    Mc Crudden MTC; Larrañeta E; Clark A; Jarrahian C; Rein-Weston A; Lachau-Durand S; Niemeijer N; Williams P; Haeck C; McCarthy HO; Zehrung D; Donnelly RF
    J Control Release; 2018 Dec; 292():119-129. PubMed ID: 30395897
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Improving Adherence to the Target Window for Cabotegravir + Rilpivirine Long-Acting Injections Through the CHORUS™ App and Web Portal: A Cluster Randomized Trial.
    Wohlfeiler MB; Brunet L; Cochran Q; Fusco JS; Hsu RK; Fusco GP
    J Int Assoc Provid AIDS Care; 2024; 23():23259582241245223. PubMed ID: 38613372
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Direct switch from an efavirenz-based regimen to intramuscular long-acting cabotegravir plus rilpivirine: A case report.
    Senkoro E; Bracchi M; Heskin J; Walters Y; Varadarajan M; Antoniadi C; Al-Shakarchi Y; Girometti N; Boffito M
    Int J STD AIDS; 2024 Mar; 35(4):311-313. PubMed ID: 37997937
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Design, Formulation, and Evaluation of Novel Dissolving Microarray Patches Containing Rilpivirine for Intravaginal Delivery.
    Mc Crudden MTC; Larrañeta E; Clark A; Jarrahian C; Rein-Weston A; Creelman B; Moyo Y; Lachau-Durand S; Niemeijer N; Williams P; McCarthy HO; Zehrung D; Donnelly RF
    Adv Healthc Mater; 2019 May; 8(9):e1801510. PubMed ID: 30838804
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Implementation of a Pharmacist-Led, Long-Acting, Injectable Cabotegravir/Rilpivirine Program for HIV-1 at Health System-Based Clinics in the New York Metropolitan Area.
    Nguyen NM; Kavanagh R; Gozar M; Cabral D; Goetz H; Cha A; McGowan JP; Pao ML
    AIDS Patient Care STDS; 2024 Mar; 38(3):115-122. PubMed ID: 38471090
    [TBL] [Abstract][Full Text] [Related]  

  • 8. HPLC-MS method for simultaneous quantification of the antiretroviral agents rilpivirine and cabotegravir in rat plasma and tissues.
    Ramöller IK; Abbate MTA; Vora LK; Hutton ARJ; Peng K; Volpe-Zanutto F; Tekko IA; Moffatt K; Paredes AJ; McCarthy HO; Donnelly RF
    J Pharm Biomed Anal; 2022 May; 213():114698. PubMed ID: 35259714
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Asian participants' experience in phase 3/3b studies of long-acting cabotegravir and rilpivirine: Efficacy, safety, pharmacokinetic, and virological outcomes through week 96.
    Oka S; Holohan V; Shirasaka T; Choi JY; Kim YS; Chamay N; Patel P; Polli JW; Ford SL; Crauwels H; Garside L; D'Amico R; Latham C; van Solingen-Ristea R; Baugh B; van Wyk J
    HIV Med; 2024 Mar; 25(3):381-390. PubMed ID: 38147871
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Implementation of long-acting cabotegravir and rilpivirine: primary results from the perspective of staff study participants in the Cabotegravir And Rilpivirine Implementation Study in European Locations.
    Gutner CA; Hocqueloux L; Jonsson-Oldenbüttel C; Vandekerckhove L; van Welzen BJ; Slama L; Crusells-Canales M; Sierra JO; DeMoor R; Scherzer J; Ait-Khaled M; Bontempo G; Gill M; Patel N; D'Amico R; Hove K; Baugh B; Barnes N; Hadi M; Low EL; Anand SB; Hamilton A; Garges HP; Czarnogorski M
    J Int AIDS Soc; 2024 Jul; 27(7):e26243. PubMed ID: 38978405
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Indirect comparison of 48-week efficacy and safety of long-acting cabotegravir and rilpivirine maintenance every 8 weeks with daily oral standard of care antiretroviral therapy in participants with virologically suppressed HIV-1-infection.
    Chounta V; Snedecor SJ; Wu S; Van de Velde N
    BMC Infect Dis; 2022 May; 22(1):428. PubMed ID: 35508986
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hydrogel-forming microarray patches with cyclodextrin drug reservoirs for long-acting delivery of poorly soluble cabotegravir sodium for HIV Pre-Exposure Prophylaxis.
    Volpe-Zanutto F; Vora LK; Tekko IA; McKenna PE; Permana AD; Sabri AH; Anjani QK; McCarthy HO; Paredes AJ; Donnelly RF
    J Control Release; 2022 Aug; 348():771-785. PubMed ID: 35738464
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Intramuscular cabotegravir and rilpivirine concentrations after switching from efavirenz-containing regimen.
    Bettonte S; Berton M; Stader F; Battegay M; Marzolini C
    Br J Clin Pharmacol; 2023 Dec; 89(12):3618-3628. PubMed ID: 37522811
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cabotegravir/Rilpivirine: the last FDA-approved drug to treat HIV.
    Taki E; Soleimani F; Asadi A; Ghahramanpour H; Namvar A; Heidary M
    Expert Rev Anti Infect Ther; 2022 Aug; 20(8):1135-1147. PubMed ID: 35596583
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Frequency of genotypic factors possibly associated with cabotegravir/rilpivirine failure in antiretroviral treatment-naïve and -experienced HIV-1- infected population.
    Scheibe K; Urbańska A; Serwin K; Parczewski M
    Infect Genet Evol; 2022 Oct; 104():105358. PubMed ID: 36057423
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Practical dosing guidance for the management of clinician-administered injections of long-acting cabotegravir and rilpivirine.
    Patel P; Teichner P; Elliot E; Boffito M; Murray M; Polli JW; Baker M; Ford SL; Han K; Russu A; Crauwels H; D'Amico RD; Spreen WR; van Wyk J
    Ther Adv Infect Dis; 2023; 10():20499361231214626. PubMed ID: 38107552
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Patient-Reported Outcomes Through 1 Year of an HIV-1 Clinical Trial Evaluating Long-Acting Cabotegravir and Rilpivirine Administered Every 4 or 8 Weeks (ATLAS-2M).
    Chounta V; Overton ET; Mills A; Swindells S; Benn PD; Vanveggel S; van Solingen-Ristea R; Wang Y; Hudson KJ; Shaefer MS; Margolis DA; Smith KY; Spreen WR
    Patient; 2021 Nov; 14(6):849-862. PubMed ID: 34056699
    [TBL] [Abstract][Full Text] [Related]  

  • 18. An evaluation of long-acting cabotegravir + rilpivirine for the treatment of virologically suppressed adults living with HIV.
    Qazzaz H; Parganas C; Cory TJ
    Expert Opin Pharmacother; 2022 Sep; 23(13):1485-1495. PubMed ID: 36124818
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Modelling the intradermal delivery of microneedle array patches for long-acting antiretrovirals using PBPK.
    Rajoli RKR; Flexner C; Chiong J; Owen A; Donnelly RF; Larrañeta E; Siccardi M
    Eur J Pharm Biopharm; 2019 Nov; 144():101-109. PubMed ID: 31525446
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Formulation of antiretroviral nanocrystals and development into a microneedle delivery system for potential treatment of HIV-associated neurocognitive disorder (HAND).
    Abbate MTA; Ramöller IK; Sabri AH; Paredes AJ; Hutton AJ; McKenna PE; Peng K; Hollett JA; McCarthy HO; Donnelly RF
    Int J Pharm; 2023 Jun; 640():123005. PubMed ID: 37142137
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.